


MISSION: SNJ Pharma Inc. (SNJ) was founded to revolutionize the treatment of thrombotic disorders with SNJ101, the first plasmin-independent thrombolytic agent. We are determined to overcome the limitations of current FDA-approved thrombolytic therapies by eliminating their associated bleeding complications and providing a new treatment option for patients suffering from thrombotic diseases.

Business Description: SNJ is a biotech company that specializes in developing and managing treatments for ischemic diseases caused by blood clots. Blood clot generation, also known as thrombosis, is the underlying pathology of major cardiovascular disorders such as ischemic heart disease (IHD), acute ischemic stroke (AIS), and venous thromboembolism (VTE) such as pulmonary embolism (PE) and deep vein thrombosis (DVT). The current thrombolytic treatments available, tissue plasminogen activators (tPA), have significant bleeding risks and are only available to fewer than 10% of patients due to significant bleeding risks associated with these therapies. SNJ Pharma’s innovative drug SNJ101 aims to revolutionize the treatment of ischemic diseases by addressing the bleeding complications associated with current thrombolytic therapies, providing a therapeutic option for over 200 million patients.

Company: SNJ was founded in 2020 by Dr. Hyeon J Kim, the inventor of patent for SNJ101, at the BioLabs-LA within the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The company’s portfolio, which includes SNJ101 for thrombolysis, aims to address unmet medical needs related to severe thrombotic and thromboembolic conditions, with a focus on improved safety and decreased side effects.

MARKET & COMMERCIALIZATION STRATEGY: It is estimated that over 126.5 million individuals suffer from IHD and 104.2 million people experience AIS annually without effective treatment, resulting in one in four deaths globally. The target market for SNJ101 is projected to be valued at US\$ 25 Billion.



TECHNICAL & COMPETITIVE ADVANTAGE: SNJ101 is a recombinant HtrA1 (High-Temperature Requirement A1) protein that exhibits specific thrombolytic activity through a plasmin-independent pathway (*Circulation Research* 2021; 128:386, PMID: 33292062).

SNJ101 has been demonstrated to be safer than tPA in animal studies, as it does not generate plasmin, does not disrupt normal wound healing, does not cause abnormal bleeding or hemorrhage, and has superior efficacy compared to current thrombolytic therapies.

REGULATORY STRATEGY & INTELLECTUAL PROPERTY

SNJ is eligible for the FDA’s expedited Drug Approval programs due to its advantages over tPA, including improved effectiveness on serious outcomes and lesser side effects. This designation will expedite the regulatory process for SNJ101.

The intellectual property of SNJ101 is protected by 2 fully issued patents and 9 pending patents worldwide.

KEY MILESTONES

- 06/2024: IND-enabling preclinical study
- 12/2024: Expedited Approval Designation
- 12/2025: IND application submission

FINANCING

- 2022 NIH NINDS SBIR Ph. I Grant (\$495K)
- 2024 NIH NINDS SBIR Ph. II Pending (\$3M)
- Seeking \$2M for IND submission